Kenneth A. Sorensen, Ph.D. is a noted biotechnology entrepreneur, investor, financier, and research scientist. Ken combines a data-driven analytic approach with high-quality research results and talented business development team members to achieve his long-term vision of unlocking new areas of biotechnology innovation. Ken has successfully raised more than $1 billion of capital and transactions to enable new biotechnology companies to move from scientific concept to commercialized products.

Ken founded Array Capital Management LLC in 2000, a life sciences merchant bank with two de novo investment funds. Each of those funds’ investment returns significantly outperformed all relevant life sciences indices. Prior to founding Array, Ken was the Portfolio Manager of the Ariane Fund, an investment fund focused on the life sciences. He was responsible for the turnaround of Ariane by reorganizing the fund, raising all new investment monies, and generating double-digit returns each year.

Earlier in his career, Ken was also recruited to the U.S. Patent and Trademark Office (USPTO) by Commissioner Lehman to work on the Human Genome Policy steering body and to serve as a Biotechnology Patent Examiner. Ken’s input regarding the non-patentability of human genes was instrumental in developing constructive patent policy that has preserved incentives to discover and develop new biotechnologies and fueled research efforts ever since. He is also a designated patent agent.

Ken is a recipient of a dual B.S. in Molecular and Organismal Biology from the University of Kansas and a Ph.D. in Developmental Neurobiology from the University of Arizona.